125459 May 2026
: Checking if the patient might "shed" or spread the virus/vector through secretions.
: This guideline is a cornerstone for developers of Advanced Therapy Medicinal Products (ATMPs) in the European Union. 125459
: Characterizing potential immune responses to the viral vector or the new protein produced by the therapy. : Checking if the patient might "shed" or
: Evaluating whether the viral vector or therapeutic gene could unintentionally be passed on to future generations. 125459
: Defining scientific principles for non-clinical studies specifically for gene therapies, which differ significantly from conventional pharmaceuticals. Key Safety Requirements :